TI
ACRS icon

Turner Investments’s Aclaris Therapeutics ACRS Stock Holding History

Turner Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-750
Closed -$20K – 215
2016
Q4 		$20K Buy
+750
New +$19.1K 0.01% 254
2016
Q2 		– Sell
-87,004
Closed -$1.65M – 201
2016
Q1 		$1.65M Buy
87,004
+29,310
+51% +$560K 0.45% 79
2015
Q4 		$1.55M Buy
+57,694
New +$1.12M 0.32% 91

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Turner Investments's ACRS Position: Q1 2017 in Review

Turner Investments sold out of Aclaris Therapeutics (ACRS) in Q1 2017, closing a stake of 750 shares — an estimated $20K sold.

Turner Investments first reported a position in ACRS in Q4 2015 and held it in 3 quarters. The position peaked at $1.65M in Q1 2016. 110 funds tracked by Wall St. Rank hold ACRS as of Q1 2017.

  • Turner Investments reported no remaining Aclaris Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Turner Investments sold 750 Aclaris Therapeutics shares in Q1 2017, an estimated $20K.
  • Turner Investments first reported a position in Aclaris Therapeutics in Q4 2015 and held it in 3 quarters.
  • Turner Investments's Aclaris Therapeutics position peaked at $1.65M in Q1 2016.
  • 110 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.